Table 4.
Comparison of Clinical features between Crohn diseases (CD) patients with and without advanced liver fibrosis
| Characteristic | Advanced fibrosis | No advanced fibrosis | P value |
|---|---|---|---|
| Count | 20 | 14 | |
| Age at NAFLD diagnosis, years | 54 [49–62] | 48 [31–55] | 0.03 |
| Duration of Crohn’s Disease (months) | 264 [48–357] | 161 [68–248] | 0.31 |
| Female gender | 43% | 70% | 0.11 |
| White race | 100% | 90% | 0.50 |
| Body Mass Index (BMI), Kg/m2 | 32 [29–35] | 34 [27–41] | 0.41 |
| Hypertension | 36% | 35% | 0.99 |
| Statin use | 43% | 20% | 0.25 |
| Diabetes Mellitus | 57% | 15% | 0.02 |
| Crohn’s disease characteristics | 0.16 | ||
| Crohn’s Disease Location | |||
| L1: Ileal | 14% | 20% | |
| L2: Colonic | 14% | 40% | |
| L3: Ileocolonic | 71% | 40% | |
| Fistulizing disease | 7% | 25% | 0.36 |
| Perianal disease | 29% | 40% | 0.72 |
| Extraintestinal Manifestations | 0% | 15% | 0.25 |
| Prior Intestinal Surgery | 71% | 55% | 0.33 |
| Multiple Prior Surgeries (> 1) | 57% | 20% | 0.04 |
| Aminosalicylic Acid (ASA) | 86% | 65% | 0.25 |
| Corticosteroid use | 79% | 90% | 0.63 |
| Azathioprine use | 50% | 65% | 0.38 |
| Methotrexate use | 0% | 5% | 0.99 |
| Biological use | 43% | 55% | 0.49 |
Descriptive statistics are reported as column percentages
NAFLD, Non-alcoholic fatty liver disease
P values are obtained from chi-square or Fisher’s exact tests